Rapamycin (off-label longevity)

Tier 3 — weak evidence · Anti-aging · mTOR inhibition · Experimental

An FDA-approved immunosuppressant being studied off-label for longevity at weekly low doses. Inhibits mTOR signalling, which is the most consistently life-extending intervention across all species tested. The PEARL trial and multiple ongoing human longevity trials are investigating weekly 5–6 mg doses. Significant side effects include immunosuppression, impaired wound healing, and metabolic disruption. Requires medical supervision.

Dose: REQUIRES PHYSICIAN SUPERVISION; experimental off-label protocol: 5–6 mg weekly; FDA-approved only as an immunosuppressant